ERBB2 and breast carcinoma: In the DESTINY-Breast03 trial, T-DXd demonstrated superior progression-free survival (PFS) compared to trastuzumab emtansine (T-DM1) in the second-line setting (28.8 months vs 6.8 months), making it the standard of care for metastatic HER2-positive breast cancer in this context.7